COMMITMENTS AND CONTINGENCIES (Details)			3 Months Ended		12 Months Ended
	Apr. 01, 2019 USD ($)	Dec. 19, 2012 USD ($)	Mar. 31, 2023 USD ($) Facility Center Term	Mar. 31, 2022 USD ($)	Dec. 31, 2021 Facility
Vendor and Licensor Commitments [Abstract]
Number of FDA-licensed plasma collection facilities approved | Facility			5
Number of FDA Inspections | Facility					2
Plasma supply agreement term			10 years
Plasma purchased from Grifols			$ 11,600,000	$ 15,500,000
Percentage of inventory purchases			40.00%	75.00%
Post-Marketing Commitments [Abstract]
Research and Development Expense	$ 1,500,000		$ 855,351	$ 624,111
BIVIGAM [Member]
Post-Marketing Commitments [Abstract]
Research and Development Expense			400,000	400,000
ASCENIV [Member]
Post-Marketing Commitments [Abstract]
Research and Development Expense			$ 200,000	$ 100,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | International Customers [Member]
Vendor and Licensor Commitments [Abstract]
Concentration risk, percentage			7.00%	6.00%
Minimum [Member]
Post-Marketing Commitments [Abstract]
Research and Development Expense		$ 1,500,000
Maximum [Member]
Post-Marketing Commitments [Abstract]
Research and Development Expense		$ 2,000,000
2011 Plasma Purchase Agreement [Member]
Vendor and Licensor Commitments [Abstract]
Plasma purchase agreement term			10 years
Number of renewal terms | Term			2
Plasma purchase agreement renewal period			5 years
Number of plasma collection centers that collects RSV Plasma which were transferred to BPC | Center			2
Percentage of plasma purchase price equal to cost			5.00%
2011 Plasma Purchase Agreement [Member] | Maximum [Member]
Vendor and Licensor Commitments [Abstract]
Number of plasma collection facilities | Facility			5
2017 Plasma Purchase Agreement [Member]
Vendor and Licensor Commitments [Abstract]
Number of plasma collection facilities | Facility			10